Transmucosal Drug Delivery Systems Market Growth, Size 2031

[Research Report] The transmucosal drug delivery systems market size is expected to grow from US$ 80.21 billion in 2023 to US$ 129.46 billion by 2031; it is estimated to register a CAGR of 6.2% from 2023 to 2031.

Analyst Viewpoint

Transmucosal drug delivery involves mucosal membranes such as oral mucosa, nasal mucosa, rectal mucosa, vaginal mucosa, ocular mucosa, and pulmonary mucosa for drug administration. Higher bioavailability, rapid onset of action, evasion of first-pass metabolism, and ease of administration are the key advantages of this drug delivery system over traditional routes of drug administration. The report includes growth prospects owing to the current transmucosal drug delivery systems market trends and their foreseeable impact during the forecast period.

Factors Driving Transmucosal Drug Delivery Systems Market Growth

Transmucosal drug delivery is a preferred route of drug administration owing to the sustained efficacy of this type of delivery. Transmucosal routes such as intranasal, buccal, sublingual, and rectal are noninvasive methods of the systemic delivery of drugs. They are particularly useful as caregivers or patients can administer these drugs without the need for expert personnel. Moreover, a rapid onset of action with reduced first-pass metabolism makes them ideal for palliative and end-of-life care. They work fast to relieve symptoms and offer patients quick relief. As a result, transmucosal delivery systems have become a popular choice in the management of various chronic diseases, such as cardiovascular diseases, diabetes, and chronic respiratory diseases. As per an article published by PubMed Central in January 2020, a study was carried out for the investigation and comparison of the safety and pharmacokinetics of dihydroergotamine (DHE) when administered in the form of intranasal DHE powder (STS101), intranasal DHE spray (Migranal), and intramuscular (IM) DHE injection in healthy subjects. The study concluded that STS101 is an easy-to-administer, non‐injected, acute treatment for migraine with a favorable tolerability profile. It is further expected to facilitate rapid and consistent pain relief, and suppress migraine symptoms without recurrence.

Numerous pharmacological drugs are offered as oral transmucosal formations; these include cardiovascular agents, sedatives, and analgesics. Biodegradable oral films aid in drug delivery to the systemic circulation, which is highly advantageous for individuals with dysphagia, repeated vomiting, hypertension, heart attack, asthma, nausea, paralysis, and mental disorders. These oral fast-dissolving films are thin adhesive strips that are placed on the patient's tongue or any oral mucosal tissue.

Therefore, advantages such as ease of administration, high bioavailability, systemic drug availability, and rapid action fuel the transmucosal drug delivery systems market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Transmucosal Drug Delivery Systems Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope

The "Global Transmucosal Drug Delivery Systems Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on global market trend analysis. The report aims to provide an overview of the market with detailed market segmentation based on systems, end user, and geography. It provides key statistics on the leading market players as well as mentions key trends and opportunities prevailing in the market. The scope of the global transmucosal drug delivery systems market report entails North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Systems-Based Insights

Based on systems, the market is segmented into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held the largest transmucosal drug delivery systems market share in 2023 and is anticipated to register the highest CAGR from 2023 to 2031.

End User-Based Insights

Based on end user, the market is segmented into healthcare facilities, homecare settings, and others. The healthcare facilities segment held the largest market share in 2023. This can be attributed to the availability of better facilities and skilled physicians in hospitals. Further, the homecare settings segment is anticipated to hold the highest CAGR from 2023 to 2031.

Regional Analysis

Based on geography, the market is primarily segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. In terms of revenue, North America held the largest transmucosal drug delivery systems market share in 2023. The US dominates the market in this region. This can be attributed to the increasing cases of chronic diseases such as diabetes, asthma, and cardiac diseases as well as the growing number of product launches by key players.

Transmucosal Drug Delivery Systems Market Regional Insights

The regional trends and factors influencing the Transmucosal Drug Delivery Systems Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Transmucosal Drug Delivery Systems Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Transmucosal Drug Delivery Systems Market Report Scope

Transmucosal Drug Delivery Systems Market Players Density: Understanding Its Impact on Business Dynamics

The Transmucosal Drug Delivery Systems Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Transmucosal Drug Delivery Systems Market are:

1. Teva Pharmaceutical Industries Ltd
2. Cigna Corporation
3. BioDelivery Sciences International, Inc
4. 3M
5. Henkel Finland Oy

Disclaimer: The companies listed above are not ranked in any particular order.

Industry Developments and Future Opportunities:

The transmucosal drug delivery systems market forecast can help stakeholders in this marketplace plan their growth strategies. As per company press releases, a few strategic developments by leading players operating in the global market are listed below:

• In February 2024, Aquestive Therapeutics, Inc. presented a poster at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting in Washington, DC, highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two complete clinical studies on sublingual Anaphylm (epinephrine) film.
• In August 2022, iX Biopharma Ltd launched IXB-322, a new program to expand its pipeline. The program aims to develop a sublingual dexmedetomidine wafer for the treatment of agitation in dementia and other indications. This initiative is part of iX Biopharma's strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform technology.
• In May 2021, Tillotts Pharma AG, a part of the Japanese Zeria Group, added a new medication to its gastroenterology portfolio with the launch of AsacolTM 1g (mesalazine). The high-strength suppository is used to treat mild to moderate ulcerative proctitis symptoms in adults. This launch will help the company offer innovative therapies to patients with gastrointestinal diseases. AsacolTM 1g suppositories provide a convenient form of treatment for individuals suffering from ulcerative proctitis, as they only require a single daily dose.
• In April 2021, Teva Pharmaceuticals USA, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the release of its generic version of Casana 1 (mesalamine) suppository medicine. The medicine is indicated for the treatment of active ulcerative proctitis (ulcerative rectal colitis) in the US.

Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finland Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; and Noven Pharmaceuticals, Inc are a few of the key companies profiled in the transmucosal drug delivery systems market report. These leading players focus on expanding and diversifying their market presence and clientele, tapping business opportunities in the market.